Literature DB >> 30582271

A randomized multicenter study on ambulatory blood pressure and arterial stiffness in patients treated with valsartan/amlodipine or nifedipine GITS.

Shao-Kun Xu1, Qi-Fang Huang1, Wei-Fang Zeng1, Chang-Sheng Sheng1, Yan Li1, Ji-Guang Wang1.   

Abstract

In a pre-specified subgroup analysis of a 12-week randomized multicenter study, we investigated effects of valsartan/amlodipine 80/5 mg single-pill combination (n = 75) and nifedipine GITS 30 mg (n = 75) on ambulatory blood pressure (BP) and arterial stiffness assessed by brachial-ankle pulse wave velocity (PWV) in patients with uncontrolled hypertension. At week 12, the between-treatment mean differences in systolic/diastolic BP were smaller for 24-hour and daytime (-2.1/-1.7 and -2.0/-1.5 mm Hg, respectively, P ≥ 0.22) but greater (P < 0.01) for nighttime (-4.0/-2.8 mm Hg, P ≤ 0.09), especially in sustained uncontrolled hypertension (-5.0/-4.1 mm Hg, P ≤ 0.04) and non-dippers (-6.5/-3.7 mm Hg, P ≤ 0.07), in favor of valsartan/amlodipine. At week 12, PWV was significantly reduced from baseline by valsartan/amlodipine (n = 59, P < 0.0001) but not nifedipine (n = 59, P = 0.06). The changes in PWV were significantly associated with that in ambulatory systolic BP and pulse pressure in the nifedipine (P ≤ 0.0008) but not valsartan/amlodipine group (P ≥ 0.57), with a significant interaction (P ≤ 0.045). The valsartan/amlodipine combination was more efficacious than nifedipine GITS in lowering nighttime BP in sustained uncontrolled hypertension and non-dippers, and in lowering arterial stiffness independent of BP lowering. ©2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ambulatory blood pressure; amlodipine; arterial stiffness; single-pill combination; valsartan

Mesh:

Substances:

Year:  2018        PMID: 30582271      PMCID: PMC8030622          DOI: 10.1111/jch.13457

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  28 in total

Review 1.  European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement.

Authors:  Eoin O'Brien; Roland Asmar; Lawrie Beilin; Yutaka Imai; Jean-Michel Mallion; Giuseppe Mancia; Thomas Mengden; Martin Myers; Paul Padfield; Paolo Palatini; Gianfranco Parati; Thomas Pickering; Josep Redon; Jan Staessen; George Stergiou; Paolo Verdecchia
Journal:  J Hypertens       Date:  2003-05       Impact factor: 4.844

2.  Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement.

Authors:  Akira Yamashina; Hirofumi Tomiyama; Kazuhiro Takeda; Hideichi Tsuda; Tomio Arai; Kenichi Hirose; Yutaka Koji; Saburoh Hori; Yoshio Yamamoto
Journal:  Hypertens Res       Date:  2002-05       Impact factor: 3.872

3.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

4.  Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

Authors:  Neil R Poulter; Hans Wedel; Björn Dahlöf; Peter S Sever; D Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren; Stuart Pocock
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

5.  Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience.

Authors:  Alexandros Briasoulis; George Bakris
Journal:  J Hypertens       Date:  2013-08       Impact factor: 4.844

6.  2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  J Hypertens       Date:  2018-10       Impact factor: 4.844

7.  Blood pressure in relation to interactions between sodium dietary intake and renal handling.

Authors:  Jun Zou; Yan Li; Chong-Huai Yan; Fang-Fei Wei; Lu Zhang; Ji-Guang Wang
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

8.  Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study.

Authors:  Pierre Boutouyrie; Assya Achouba; Patrick Trunet; Stéphane Laurent
Journal:  Hypertension       Date:  2010-04-19       Impact factor: 10.190

9.  Effect of long-term antihypertensive treatment on white-coat hypertension.

Authors:  Giuseppe Mancia; Rita Facchetti; Gianfranco Parati; Alberto Zanchetti
Journal:  Hypertension       Date:  2014-09-22       Impact factor: 10.190

Review 10.  Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension.

Authors:  Scott S Billecke; Pamela A Marcovitz
Journal:  Vasc Health Risk Manag       Date:  2013-03-16
View more
  5 in total

1.  Low-dose combination therapy to control sustained ambulatory hypertension-Basic principles and future directions.

Authors:  Panagiotis I Georgianos; Vassilios Liakopoulos; Pantelis E Zebekakis
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-24       Impact factor: 3.738

2.  A randomized multicenter study on ambulatory blood pressure and arterial stiffness in patients treated with valsartan/amlodipine or nifedipine GITS.

Authors:  Shao-Kun Xu; Qi-Fang Huang; Wei-Fang Zeng; Chang-Sheng Sheng; Yan Li; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-24       Impact factor: 3.738

3.  A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension.

Authors:  Qi-Fang Huang; Chang-Sheng Sheng; Yan Li; Yu Dou; Mei-Sheng Zheng; Zhi-Ming Zhu; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-04-11       Impact factor: 3.738

4.  What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?

Authors:  Ji-Guang Wang; Yook-Chin Chia; Chen-Huan Chen; Sungha Park; Satoshi Hoshide; Naoko Tomitani; Tomoyuki Kabutoya; Jinho Shin; Yuda Turana; Arieska Ann Soenarta; Jam Chin Tay; Peera Buranakitjaroen; Jennifer Nailes; Huynh Van Minh; Saulat Siddique; Jorge Sison; Guru Prasad Sogunuru; Apichard Sukonthasarn; Boon Wee Teo; Narsingh Verma; Yu-Qing Zhang; Tzung-Dau Wang; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-19       Impact factor: 3.738

Review 5.  Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment.

Authors:  Concetta Altamura; Maria Raffaella Greco; Maria Rosaria Carratù; Rosa Angela Cardone; Jean-François Desaphy
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.